VCEL - ヴェリセル （Vericel Corporation）

Vericel Corporation (NASDAQ:NASDAQ:VCEL) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ETCompany ParticipantsEric Burns - Vice President, Finance and Investor RelationsNick…

The following slide deck was published by Vericel Corporation in conjunction with their 2023 Q1 earnings call.

In 2022, Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function. Northbrook, IL 60062 -- ( SBWIRE ) -- 05/10/2023 -- The Global Regenerative Medicine Market in terms of revenue was estimated to be worth $12.2 Billion in 2022 and is poised to grow at a CAGR of 27.2% from 2022 to 2027. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and issues associated with commercialization and regulatory compliance factors are expected to restrain the market growth during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579 Regenerative Medicine Industry Dynamics Drivers: Availability of funding and rising investments in R&D The rising need for improved therapies for cancer, diabetes, skin diseases, musculoskeletal diseases, chronic wounds, burns, and CVD has resulted in increased research activities.

Vericel (NASDAQ: VCEL ) reported its Q1 earnings results on Wednesday, May 10, 2023 at 07:55 AM. Here''s what investors need to know about the announcement. Earnings Vericel missed estimated earnings by 6.67%, reporting an EPS of $-0.16 versus an … Full story available on Benzinga.com

Vericel press release (VCEL): Q1 GAAP EPS of -$0.16 misses by $0.01.Revenue of $41.01M (+13.7% Y/Y) beats by $3.64M.Full-Year 2023 Revenue Guidance Raised to $184-$192…

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Vericel Corporation is an innovative leader with a strong pipeline of FDA-approved and investigational products that address unmet medical needs. Click here to read more.

A share of Vericel Corporation (NASDAQ:VCEL) closed at $29.61 per share on Thursday, down from $30.48 day before. While Vericel Corporation has underperformed by -2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -19.03%, with highs and lows ranging from $41.24 to $17.30, […]

https://www.investing.com/news/pro/vericel-corporation-pt-raised-to-31-at-truist-securities-432SI-3015443

The share price of Vericel Corporation (NASDAQ:VCEL) rose to $30.60 per share on Thursday from $28.52. While Vericel Corporation has overperformed by 7.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -8.05%, with highs and lows ranging from $43.97 to $17.30, whereas the […]

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.

Vericel Corporation is an innovative leader with a strong pipeline of FDA-approved and investigational products that address unmet medical needs. Click here to read more.

A share of Vericel Corporation (NASDAQ:VCEL) closed at $29.61 per share on Thursday, down from $30.48 day before. While Vericel Corporation has underperformed by -2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -19.03%, with highs and lows ranging from $41.24 to $17.30, […]

https://www.investing.com/news/pro/vericel-corporation-pt-raised-to-31-at-truist-securities-432SI-3015443

The share price of Vericel Corporation (NASDAQ:VCEL) rose to $30.60 per share on Thursday from $28.52. While Vericel Corporation has overperformed by 7.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VCEL fell by -8.05%, with highs and lows ranging from $43.97 to $17.30, whereas the […]